Palatin Technologies, Inc. (PTN) analyst actions
Rating and price-target actions on PTN in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the PTN overview →
2 measured PTN analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED) | Press release | -0.71% | -9.62% | |
| Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity | Press release | +0.00% | +3.68% |
Keep exploring
More PTN: earnings → · SEC filings → · PTN overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Cardax, Inc. (CDXI) | 177 | 0.00% | 13% |
| NRC Health (NRC) | 177 | -0.16% | 38% |
| Rafael Holdings, Inc. Class B (RFL) | 176 | 0.00% | 43% |
| Strata Skin Sciences, Inc. (SSKN) | 176 | 0.00% | 39% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.